Intuitive Surgical (ISRG) Stock
Leader in robotic surgery with high margin recurring revenue. Here's the price, business snapshot, and what's worth knowing about Intuitive Surgical in June 2026.
Intuitive Surgical (ISRG) is the dominant name in robotic-assisted surgery, best known for its da Vinci surgical systems that enable minimally invasive procedures. With a sizeable installed base and recurring revenue from instruments, accessories and service contracts, the company has built a high-margin business that benefits as hospitals upgrade systems and expand robotic programmes. Key growth drivers include wider clinical adoption across specialties, new product introductions and expansion into less invasive procedures. Investors should weigh these opportunities against concentration risks — substantial reliance on a single product family, ongoing R&D spending, regulatory and reimbursement dynamics, and sensitivity to hospital capital budgets. Competition from established medical groups and new robotics entrants is rising. The market cap (~$165.9bn) reflects premium expectations of persistent growth and margin expansion; such expectations can reverse. This overview is educational and not investment advice — consider your risk tolerance and seek personalised guidance before acting.
Why It's Moving
ISRG Stock Forecast 2026: Why Analysts See Roughly +24% Upside From Current Levels
- Wall Street coverage broadly clusters around a mid‑ to high‑500s price target, implying roughly 20–25% potential upside from recent trading levels, signaling that analysts still see the stock as undervalued relative to long‑term earnings and margin expectations.
- Recent commentary highlights continued strength in procedure volumes and recurring instrument revenue, which supports the thesis that Intuitive’s installed Da Vinci base will keep driving high‑margin, repeatable cash flows rather than one‑time equipment sales.
- Sector‑wide tailwinds in robotic‑assisted surgery—including higher hospital adoption and more procedures across specialties—underpin the bullish sentiment, with many analysts framing ISRG as a core leadership name in an expanding, technologically driven healthcare subsector.
ISRG Stock Forecast 2026: Why Analysts See Roughly +24% Upside From Current Levels
- Wall Street coverage broadly clusters around a mid‑ to high‑500s price target, implying roughly 20–25% potential upside from recent trading levels, signaling that analysts still see the stock as undervalued relative to long‑term earnings and margin expectations.
- Recent commentary highlights continued strength in procedure volumes and recurring instrument revenue, which supports the thesis that Intuitive’s installed Da Vinci base will keep driving high‑margin, repeatable cash flows rather than one‑time equipment sales.
- Sector‑wide tailwinds in robotic‑assisted surgery—including higher hospital adoption and more procedures across specialties—underpin the bullish sentiment, with many analysts framing ISRG as a core leadership name in an expanding, technologically driven healthcare subsector.
When is the next earnings date for INTUITIVE SURGICAL INC (ISRG)?
The next ISRG earnings report is estimated for July 28, 2026; some calendars place it in the July 17–23, 2026 window based on historical timing. It will cover Q2 2026. Intuitive Surgical has not officially confirmed the date yet, so the timing remains an estimate.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Intuitive Surgical's stock with a target price of $606.9, indicating growth potential.
Financial Health
Intuitive Surgical is achieving strong revenue, profit margins, and cash flow, showcasing solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring ISRG
Niche Dominators
These carefully selected companies rule their specialized markets by design. They've built powerful competitive advantages in focused segments that larger companies often overlook, creating a path to consistent profits and sustainable growth.
Published: June 17, 2025
Explore BasketPatient Platforms
This carefully curated collection features companies building the technological foundations that will power innovation for decades to come. Our analysts have identified businesses creating essential infrastructure in genomics, AI, robotics, and advanced computing—platforms that could define their industries and generate substantial long-term returns.
Published: June 17, 2025
Explore BasketAI & Robotics Architects
Invest in companies that own the foundational patents powering our AI future. These carefully selected stocks represent firms whose intellectual property forms the blueprint for machine learning and automation, giving them a powerful competitive advantage for years to come.
Published: June 17, 2025
Explore BasketRestless Innovators
Companies that refuse to stand still, constantly pushing boundaries and redefining what's possible. These stocks have been carefully selected by our analysts for their relentless pursuit of innovation and potential for long-term growth.
Published: June 17, 2025
Explore BasketFuture Tech: World Changing Ideas
Get ahead of tomorrow's innovations with this collection of stocks pushing technological boundaries. Our analysts have carefully selected companies developing flying cars, breakthrough medical treatments, and robotic surgery that could reshape our future.
Published: May 25, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue model
Consumables and service contracts create predictable follow-on sales, though hospital budgets and procedure volumes can affect revenue.
Innovation and R&D
Regular product updates and new platforms can open markets, but they require heavy R&D and face regulatory hurdles.
Global adoption trends
Growing use of minimally invasive surgery offers a large addressable market, yet adoption and reimbursement vary by region.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
